Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Nihon Chouzai Tender Offer Completed, Set to Delist under Advantage Partners
Nihon Chouzai said on September 17 that the tender offer for its shares by AP86, an entity affiliated with private equity firm Advantage Partners, closed on September 16 with sufficient subscriptions. AP86 will acquire a 72.8% stake in the major…
To read the full story
Related Article
BUSINESS
- Deciphera Portfolio Powers Ono to Record Sales as It Eyes Post-Opdivo Era
May 11, 2026
- Daiichi Sankyo Healthcare to Raise Prices of OTC Drugs amid Inflation
May 11, 2026
- Daiichi Sankyo Cuts FY2025 Profit Outlook on ADC Supply Plan Review
May 11, 2026
- J&J's Drug-Device Combo Offers Weeks-Long Local Therapy for Bladder Cancer: Exec
May 8, 2026
- Leqembi FY2025 Global Sales Reach 88 Billion Yen: Eisai
May 1, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…